PARIS, Sept 17 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) said on Monday its pipeline of late-stage experimental drugs was maturing but a drug for Alzheimer's disease, which analysts had viewed as high risk, failed in clinical studies.
